FDA Brief

Warning letters Drugs

FDA warning letter to

www.buycodeine.us

High riskIssued May 5, 2025Posted Jun 17, 2025Center for Drug Evaluation and Research (CDER)

FDA warned website buycodeine.us for selling unapproved, misbranded opioid and stimulant drugs online without prescriptions.

What happened

FDA reviewed the website www.buycodeine.us and found it offering Toseina (codeine phosphate hemihydrate oral solution) and Ritalina (methylphenidate hydrochloride tablets) to U.S. consumers. FDA said there are no approved applications for these products and that the site offers prescription drugs without a prescription.

What FDA found

  1. The website sold Toseina and Ritalina as unapproved new drugs (drugs without FDA approval) with no FDA-approved application.

    FD&C Act sections 301(d), 505(a) [21 U.S.C. §§ 331(d), 355(a)]
  2. The labeling for these prescription drugs did not give adequate directions for safe use by a layperson, so FDA calls them misbranded.

    FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]
  3. The website offered prescription drugs for sale without a prescription from a licensed healthcare practitioner.

    FD&C Act sections 503(b)(1), 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]

What FDA wants

FDA asks the company to stop offering unapproved and misbranded drugs to U.S. consumers and to notify FDA in writing within 15 working days describing corrective steps and how it will prevent recurrence.

Who should pay attention

  • companies selling prescription drugs online to U.S. consumers
  • brands and distributors of opioid or stimulant products
  • platforms hosting online pharmacy storefronts

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk
  4. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk